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1. Introduction 
The prescriptions containing personalised doses of medicines are of utmost importance as 
they are not prepared commercially by mass production. In the United States, 30 million 
prescriptions are prepared annually by 3000 compounding pharmacies (website, 2014). A 
study suggests the most common therapeutic problems, 76% combination not commercially 
and 43.6% strengths were commercially unavailable (Martin et al., 2009).  It is of significant 
importance to develop a dynamic dispensing system that can respond to different patient’s 
needs rapidly and effectively. 
For a preparation method to perfectly suit the demands of personalised method, a safe 
easily adjustable dispensing station should be created. The station can be operated via a 
simple user interface with minimal training and can be connected to a wider healthcare 
network (Skowyra et al., 2015). Clearly, such criteria cannot be fulfilled by conventional 
tableting methods, where multiple processing stages, large batches, use of costly facilities 
and experienced labour are common practice (Khaled et al., 2014). Tailoring such system for 
an individual patient who continuously needs to change his/her medicines dose is too 
expensive and impractical.  
The use of 3D printing as a flexible alternative technique to conventional tableting 
techniques started with the use of powder-based printing (Katstra et al., 2000; Yu et al., 
2009; Yu et al., 2007) (Ursan et al., 2013). Other printing techniques such as inkjet printing  
(Gu et al., 2012), thermal inkjet printing (Buanz et al., 2011), piezoelectric inkjet printing 
system (Lee et al., 2012), stereolithography (Melchels et al., 2010) and syringe/extrusion 3D 
printing (Rattanakit et al., 2012) has also been investigated.  
Fused deposition modelling (FDM) is a widely used and affordable bench top 3D printing 
technique (Lim, 2010). AN FDM based 3D printer uses a pre-prepared polymeric filament 
e.g. Poly Vinyl Alchohol (PVA) and guide it to pass through a heated nozzle to be extruded at 
a semi-solid state into fused 3D structure in a layer-by-layer fashion. The potential of FMD 
based 3D printers to incorporate drug molecules have been previously using commercially 
available PVA filaments (Masood, 2007) (Goyanes et al., 2014a; Goyanes et al., 2014b). Our 
research group showed the potential of this printing technology to provide a mini-
dispensing dose controlling station via manipulating the volume of the printed design 
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through input on software (Skowyra et al., 2015). However, the previous attempts suffered 
several limitations such as limited encapsulation efficiency (<2.5%), the use of non-
pharmaceutical grade ingredients, simplistic tablet designs, the use of high temperature and 
were confined to extended drug release systems (Goyanes et al., 2014a; Goyanes et al., 
2014b; Sandler et al., 2014; Skowyra et al., 2015).  
In this work, we present a combined approach of manufacturing 3D printed tablet based on 
FDM 3D printing and hot melt extrusion (HME). We explored the potential of this approach 
to accurately control the dose and in vitro release pattern of a model drug using a number 
of immediate and extended release polymers. The study was carried out using a realistic 
drug loading and a challenging capsule-shaped tablet design. 
2. Materials and methods 
2.1. Materials 
Theophylline was purchased from Arcos (UK). Eudragit® RL100 and Eudragit® RS100 
formulation were donated by Evonik Industries (Darmstadt, Germany). Hydroxypropyl 
cellulose SSL grade was donated by Nisso Chemical Europe GmbH (Dusseldorf, Germany). 
Triethyl citrate (TEC) and triacetin were supplied by Sigma-Aldrich (UK). Scotch blue 
painter’s tape 50 mm was supplied by 3M (Bracknell, UK).  
2.2. Preparation of  theophylline loaded filaments via hot-melt extrusion 
MakerBot Replicator® 2X Experimental 3D Printer (MakerBot Industries, LLC, New York, 
USA) was utilized to print theophylline tablets. In order to obtain the new formulation hot 
melt extrusion method was implemented using Thermo Scientific HAAKE MiniCTW 
(Karlsruhe, Germany). 
The compositions and the ratio of drug, polymer plasticizer mixtures are shown in Table 1. 
About 6g of total blend were carefully weighed and added gradually to counter flow twin 
screw extruder. The molten mass was allowed to mix for at least 5min to allow 
homogeneous distribution of drug and polymer within the matrix. The molten mass was 
then extruded through a die nozzle with cylindrical shape with appropriate diameters. 
Sample was fed manually using a funnel into the inlet of the extruder setting under feeding 
temperature as specified in Table 1 and speed of 80 rpm. Mixing temperature was set 
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between 110-120°C and speed of 50 rpm. Filament was extruded using control torque of 0.6 
Nm. The choice of a plasticizer for each filament was determined by literature 
recommendations. Filaments were stored in sealed plastic bags at room temperature before 
3D printing. 
2.3. Tablet design and printing process 
Blank and theophylline loaded tablets were designed in prolonged typlical capsule shape 
using Autodesk® 3ds Max® Design 2012 software version 14.0 (Autodesk, Inc., USA) and 
saved in STL format (Figs.1). The design was imported to the 3D printer’s software, 
MakerWare Version 2.4.0.17 (Makerbot Industries, LLC., USA) (Fig.1). A series of tablets with 
increasing volumes were printed by modifying the dimensions of the design: length x width 
x heights (L, H, W) without altering the ratios between these dimensions. 
2.4. Modification of 3D printer 
A MakerBot Replicator® 2X Experimental 3D Printer (MakerBot Industries, New York, USA) 
was utilized to print Eudragit RL tablets. Tablets were printed using modified settings of the 
software for PLA filament as follows: type of printer: Replicator 2X; type of filament: PLA; 
resolution: standard; temperature of building plate: 20 °C; speed of extruder 90 mm/s while 
extruding and 150 mm/s while traveling; infill: 100%; height of the layer: 200 µm. No 
supports or rafts were utilized in the printed model.  
The following modifications were implemented: 
i) Kapton tape layer (default) provided poor adhesion of the designs to the built 
plate. Blue Scotch painter’s tape was applied to the surface of the printing board 
to improve adhesion to the surface layer.  
ii) Changing extruder temperature during printing as specified in Table 1 was 
essential to maintain constant flow of theophylline loaded filaments. 
In order to study the impact of infill percentage on drug release from HPC based tablets, 
infill percentage was varied to 10, 20, 40, 60, 80 and 100%. The impact of printing speed was 
assessed by modifying the printing resolution low, standard and high while printing 250 mg 
theophylline tablet. 
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2.5. Determination of drug content  
In order to assess theophylline content in the printed tablets, each tablet was weighed and 
sonicated in 1000 ml volumetric flask containing 0.1 M HCl. The sonication period were 
extended to 8 hours to ensure complete drug extraction. Theophylline drug concentration 
was determined via spectrophotometry (Jenway, Japan) at absorbance λmax of 272 nm. For 
higher concentrations, the solution was diluted as suitable with 0.1 M HCl. 
2.6. Scanning Electron Microscopy 
The surface morphology of the printed tablet was assessed using a Quanta-200 SEM 
microscope at 20 kV. Samples were placed on metallic stubs and gold coated under vacuum 
for 2 min using JFC-1200 Fine Coater (Jeol, Tokyo, Japan), prior to imaging. 
2.7. X-Ray Powder Diffraction  
A powder X-ray diffractometer, D2 Phaser with Lynxeye (Bruker, Germany) was used to 
assess the crystallinity of theophylline in the drug loaded tablets. Samples were scanned 
from 2Theta (2θ)= 5° to 50° using 0.01° step width and a 1 second time count. The 
divergence slit was 1mm and the scatter slit 0.6mm. The wavelength of the X-ray was 0.154 
nm using Cu source. The voltage used was 30kV. Filament emission was 10 mAusing a scan 
type coupled with a two theta/theta scintillation counter over 30 min.  
2.8. Differential Scanning Calorimetry (DSC) 
A differential scanning calorimeter DSC Q2000 (TA Instruments, Elstree, Hertfordshire, UK) 
was utilized to perform thermal analysis. Samples of approximately 5 mg were accurately 
weighed and placed in a 40 µL standard aluminium pan DSC analysis. Analysis was carried on 
under a nitrogen environment (50 mL/min). In order to exclude the effect of humidity and 
to get a clearer Tg, samples were cooled to -10°C, then heated to 100 °C. The temperature 
was kept isothermal for 5 min then cooled to -20 °C and left for 2 minutes. The heating and 
cooling of the samples were performed at of 10 °C/min. This was followed by a heat scan 
from -20 °C to 300 °C at the same rate. All measurements were carried out in triplicates. The 
data was analyzed using TA 2000 analysis software. 
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All the samples were subjected to a cycle of heat/cool/heat in order to ensure accurate 
reading and drying of the polymeric matrices. Samples were kept isothermal at 100°C for 5 
minutes. This was followed by cooling step to -20°C again. Temperature was left isothermal 
for 2 minutes. Finally a heating step to 300°C was followed to measure the endothermic 
peak of theophylline if existed. All the heating and cooling sequences were carried out at a 
rate of 10°C/min. 
2.9.  Thermo Gravimetrical Analysis (TGA) 
A thermo gravimetrical analysis TGA Q5000 (TA Instruments, Elstree, Hertfordshire, UK) was 
used to measure the thermal decomposition profiles of the extruded filaments and printed 
tablets, in addition to the raw materials.  
Samples of approximately 5 mg were added to an aluminium pan in the TGA. Samples were 
heated between 25°C and 600°C with a heating rate of 10°C/min. The data was analysed 
using TA 2000 analysis software.  
2.10. In Vitro drug release study via pH change USP II dissolution test 
In vitro drug release studies for all gastro-resistant coating formulations used in this study 
were conducted in a USP II dissolution apparatus (AT 7 Smart, SOTAX, Switzerland). Each 
experiment was carried out in triplicate in dissolution medium at 37±0.5 °C with paddle 
speed of 50 rpm. The tablets were tested in 750 mL of a stimulated gastric fluid (0.1M HCl, 
pH 1.2) for 2 h, followed by 16-hour exposure to pH 6.8 phosphate buffer. Within all the 
experiment the amount of released theophylline was determined at 5 min intervals by 
UV/VIS spectrophotometer (PG Instruments Limited, UK) at the wavelength of 272 nm and 
path length of 1 mm. Data was analysed using IDISis software (Automated Lab, 2012). 
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3. Results and discussion 
Here we present a strategy for the production of tablets with immediate and extended 
release properties that allows the using of realistic high loading of drug (50%). The process is 
schematically illustrated in Fig.1. Firstly, theophylline loaded filaments were produced via 
processing a physical mixture of drug and polymer through hot-melt extrusion. Computer 
software is utilized to design a capsule-shaped tablet with different dimensions. The 
theophylline loaded filaments are utilized as a feed filament for FDM based 3D printer.  SEM 
images of 3D printed tablets showed that tablets are made of staked layers of 200 µm 
thickness (Fig. 1E).  The process takes approximately 5 min and is filmed in Video S1. 
When tablets with increasing dimensions has been used to fabricate tablets, a good 
correlation between the volume and tablet mass was achieved (R² = 0.9997) Fig. S1. This 
indicated the potential of this system to maintain efficient control of tablet mass using the 
newly fabricated filaments adapted filament. The relevant equation was utilized to fabricate 
tablets with increasing tablet mass as in equation 3. Table 2 and Figure 2 demonstrated the 
fabrication of different tablets with therapeutic dose of theophylline: 60, 120, 200, 250 and 
300mg. The tablets demonstrated a good ecstatic shape and high physical resistance 
(crushing strength >490N). The accuracy of dose was in the range of 91.34-95.92% with 
small variation co-efficient in the range of 0.8-3.4%. The printing method demonstrated a 
high correlation between the target and achieved dose (R² = 0.9995) (Fig.2B). The in vitro 
drug release pattern for theophylline indicated that drug release occurred mainly through 
diffusion mechanism. The retrieved dissolution particles indicated the formation of pores 
due to drug leaching through the system. The larger the tablet, the slower the release 
pattern. Such a trend has also been demonstrated in previous paper justa. 
The choice of printing speed appeared to have significant impact of the external appearance 
of the tablet and the thickness of deposited layer (Fig. 3A-C). SEM images indicated that low, 
standard and high printing resolution (which corresponds to faster printing speed) resulted 
in the formation layer thicknesses of 400, 200 and 100µm respectively. However, the 
printing speed appeared not to have significant influence on the variation of tablet weight 
or pattern of drug release for Eudragit RL based 3D printed tablets (Fig. 3D, E). Also, 
standard and low resolution took similar printing time while higher resolution appeared to 
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significant increase the printing time. Such a difference may have major influence when 
optimizing the printing process to minimize dispensing time while maintaining the quality of 
the 3D printed tablet.  
In order to test the applicability of this method to tailor drug release from 3D printed 
tablets, different polymer or a mixture of polymers were used in replacement of Eudragit 
RL. The details of the formulation and preparation method are available in Table 1. Two 
immediate release polymers (HPC SSL and Eudragit E) were applied. The majority of 
theophylline release took place within 25 min from both filaments Fig.3A. However, it is 
obvious in both examples that drug release was slowed down after 3D printing (compared 
to non-printed filament). This might be attributed to the loss of surface area upon printing. 
It is also possible that further thermal treatment of drug polymer filament during 3D 
printing, increased the drug-polymer interaction within polymeric matric and reduce 
chances of water imbibition upon introduction to dissolution medium. 
To test the possibility of controlling drug release mixtures of Eudragit RL with Eudragit RS or 
Eudragit E were also investigated (Fig.3 B-C). It was possible to tailor drug release from 
Eudragit RL filaments with incorporation of less permeable polymer (Eudragit RS). However, 
the incorporation of Eudragit E appeared to have little influence on drug release from 
Eudragit RL filament. It was feasible to utilize FDM 3D printing process to print these 
filaments. 
The printed tablets were analysed using thermo-gravimetric analysis in order to compare 
the thermal decomposition pattern of the printed tablet to that of the extruded filaments 
and raw materials (Fig. 5A). It was noticed that the pure polymer lost around 3% of its 
weight up to 110 °C which is believed to be the moisture content of the polymer. The 
degradation pattern of the physical mixture revealed two degradation steps (Fig. 5B). The 
first (200 °C) represents the degradation of theophylline while the (340°C) indicated the 
degradation of the Eudragit RL. It can be noticed that the degradation of the theophylline in 
the physical mixture is steeper than that of the filament or the tablet which can be related 
to the distribution and interaction of theophylline particles with the polymeric matrix. 
Printed tablets revealed that the Tg of Eudragit has shifted from about 70°C for the pure 
polymer into about 46°C for the extruded filaments and the printed tablet. The thermal 
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treatment of the filament through 3D printing appeared to have minimal effect on Tg of the 
polymer. 
These peaks are expected to be for theophylline crystals as the melting point of pure 
theophylline can be noticed at 272°C. However, the impurity effect of the polymer caused 
this slight shift in the melting endotherm. The diffraction pattern of tablets containing 
theophylline revealed diffraction peaks at 7 A°, 12 A°, 14 A° and 24 A° (Räsänen et al., 2001) 
that match the diffraction pattern of theophylline. The same diffraction pattern appeared 
with the extruded filaments from the hot melt extrusion process and in the physical mixture 
as well as it can be noticed in figure 13. The reduced intensity of the peak suggests that 
more theophylline is dissolved in the Eudragit RL matrix. 
In summary we have reported a new approach for production of flexible dose system based 
on combined approach of FDM 3D printing and HME. The realistic loading of the tablet, 
versatile control of dosing and drug release and the finishing quality of the printed tablets  
4. Conclusion 
3D printing process proved universal to different methacrylic polymers such as Eudragit RL, 
Eudragit RS and Eudragit E. It was also possible to print tablets using HPC SSL polymer. The 
use of HME based pharmaceutical filament preserved the linear relationship between the 
mass and printed volume and was utilized to effectively control the dose (R2=0.9995) and 
maintained a dose accuracy of 91-95%. Higher resolution printing quality doubled the 
printing time but offered little effect on release pattern and weight accuracy. Thermal 
analysis indicated that a potential amount of theophylline remained in a crystal form in the 
3D printed tablet with possible reduction in the crystallinity percentage compared to non-
printed filament. This could partially explain their slower drug release pattern in comparison 
with filaments.  Because of the low cost and wide-availability of FDM 3D printers, these 3D 
printers hold promise for clinical applications. 
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of theophylline, HPC SSL, physical mixture of theophylline and HPC SSL, Extruded filament of 
theophylline and HPC SSL, tablet of theophylline and HPC SSL. 
  
12 
 
List of tables 
Table 1 Processing parameters for filament production using HME and subsequent 3D printing 
Table 2 Target and actual tablet mass, volume and dimensions. 
Table 3 Target and actual theophylline dose in 3D printed Eudragit RL based tablets. 
Additional Information 
Table 1S 
Figure 1S 
Video 1S 
 
References  
Buanz, A.B., Saunders, M.H., Basit, A.W., Gaisford, S., 2011. Preparation of personalized-dose salbutamol sulphate oral 
films with thermal ink-jet printing. Pharmaceutical research 28, 2386-2392. 
Goyanes, A., Buanz, A.B., Basit, A.W., Gaisford, S., 2014a. Fused-filament 3D printing (3DP) for fabrication of tablets. 
International journal of pharmaceutics 476, 88-92. 
Goyanes, A., Buanz, A.B., Hatton, G.B., Gaisford, S., Basit, A.W., 2014b. 3D printing of modified-release aminosalicylate (4-
ASA and 5-ASA) tablets. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft 
fur Pharmazeutische Verfahrenstechnik e.V. 
Gu, Y., Chen, X., Lee, J.-H., Monteiro, D.A., Wang, H., Lee, W.Y., 2012. Inkjet printed antibiotic- and calcium-eluting 
bioresorbable nanocomposite micropatterns for orthopedic implants. Acta Biomater 8, 424-431. 
Katstra, W.E., Palazzolo, R.D., Rowe, C.W., Giritlioglu, B., Teung, P., Cima, M.J., 2000. Oral dosage forms fabricated by three 
dimensional printing. J Control Release 66, 1-9. 
Khaled, S.A., Burley, J.C., Alexander, M.R., Roberts, C.J., 2014. Desktop 3D printing of controlled release pharmaceutical 
bilayer tablets. International journal of pharmaceutics 461, 105-111. 
Lee, B.K., Yun, Y.H., Choi, J.S., Choi, Y.C., Kim, J.D., Cho, Y.W., 2012. Fabrication of drug-loaded polymer microparticles with 
arbitrary geometries using a piezoelectric inkjet printing system. Int J Pharmaceut 427, 305-310. 
Martin, K.S., McPherson, T.B., Fontane, P.E., Berry, T., Chereson, R., Bilger, R., 2009. Independent Community Pharmacists' 
Perspectives on Compounding in Contemporary Pharmacy Education. Am J Pharm Educ 73. 
Masood, S.H., 2007. Application of fused deposition modelling in controlled drug delivery devices. Assembly Autom 27, 
215-221. 
Melchels, F.P.W., Feijen, J., Grijpma, D.W., 2010. A review on stereolithography and its applications in biomedical 
engineering. Biomaterials 31, 6121-6130. 
Räsänen, E., Rantanen, J., Jørgensen, A., Karjalainen, M., Paakkari, T., Yliruusi, J., 2001. Novel identification of 
pseudopolymorphic changes of theophylline during wet granulation using near infrared spectroscopy. Journal of 
Pharmaceutical Sciences 90, 389-396. 
Rattanakit, P., Moulton, S.E., Santiago, K.S., Liawruangrath, S., Wallace, G.G., 2012. Extrusion printed polymer structures: a 
facile and versatile approach to tailored drug delivery platforms. Int J Pharm 422, 254-263. 
Sandler, N., Salmela, I., Fallarero, A., Rosling, A., Khajeheian, M., Kolakovic, R., Genina, N., Nyman, J., Vuorela, P., 2014. 
Towards fabrication of 3D printed medical devices to prevent biofilm formation. Int J Pharmaceut 459, 62-64. 
Skowyra, J., Pietrzak, K., Alhnan, M.A., 2015. Fabrication of extended-release patient-tailored prednisolone tablets via 
fused deposition modelling (FDM) 3D printing. European journal of pharmaceutical sciences : official journal of the 
European Federation for Pharmaceutical Sciences 68, 11-17. 
Ursan, I., Chiu, L., Pierce, A., 2013. Three-dimensional drug printing: A structured review. J Am Pharm Assoc 53, 136-144. 
website, W.C.M.C., 2014. Study Shows Inconsistent Dosages of Widely Used Eye Disease Drug, 
http://weill.cornell.edu/news/pr/2014/09/study-shows-inconsistent-dosages-of-widely-used-eye-disease-drug-szilard-kiss-
donald-damico.html, last accessed 10/2/2015. 
Yu, D.G., Shen, X.X., Branford-White, C., Zhu, L.M., White, K., Yang, X.L., 2009. Novel oral fast-disintegrating drug delivery 
devices with predefined inner structure fabricated by Three-Dimensional Printing. The Journal of pharmacy and 
pharmacology 61, 323-329. 
Yu, D.G., Yang, X.L., Huang, W.D., Liu, J., Wang, Y.G., Xu, H., 2007. Tablets with material gradients fabricated by three-
dimensional printing. Journal of pharmaceutical sciences 96, 2446-2456.
13 
 
Table 1 Processing parameters for filament production using HME and subsequent 3D printing 
Formulation 
(Weight ratio) 
HME process 3D Printing process 
Initial temperature (°C) Extruding temperature (°C) Extruding temperature (°C) Platform temperature (°C) 
Eudragit RL/Theophylline/TEC 
 45/50/5 
130 120 170 90 
Eudragit RS/ Theophylline /TEC 
 42.5/50/7.5 
130 110 150 60 
Eudragit E/ Theophylline /TEC 
 46.5/50/3.5 
130 110 140 60 
Eudragit RL/Eudragit E/ Theophylline /TEC 
 22.5/22.5/50/5 
130 115 140 90 
Eudragit RL/Eudragit RS/ Theophylline /TEC 
22.5/22.5/50/5 
130 120 150 90 
HPC SSL/ Theophylline /Triacetin 
 46/50/4 
125 110 160 20 
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Table 2 Target and actual tablet mass, volume and dimensions. 
Expected tablet mass (mg) Volume (mm³) Dimensions (mm) 
X x Y x Z 
Average tablet mass ±SD (mg) Weight accuracy ±SD 
(%) 
150 210.14 11.34 x 4.13 x 4.49 149.77±3.15 99.84±2.10 
300 420.27 14.29 x 5.20 x 5.66 300.53±4.23 100.18±1.41 
450 630.42 16.35 x 5.95 x 6.48 455.17±1.84 101.15±0.41 
600 840.55 18.00 x 6.55 x 7.13 613.43±4.69 102.24±0.78 
750 1050.69 19.39 x 7.06 x 7.68 774.43±8.71 103.26±1.16 
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Table 3 Target and actual theophylline dose in 3D printed Eudragit RL based tablets. 
Target dose (mg)  Tablet mass± SD (mg) Theoretical dose ±SD (mg) Achieved dose ±SD (mg) Dose accuracy ±SD (%) 
60 123.0±1.1  61.5±0.57 58.8±0.8 95.56±2.03 
125 253.7±4.5 126.9±2.26 121.7±2.3 95.92±0.80 
200 411.2±5.9  205.6±2.97 192.4±4.0 93.62±3.39 
250 516.6±10.7  258.3±5.35 237.1±1.3 91.83±2.63 
300 618.9±6.3  309.5±3.13 282.6±3.0 0-±2.01 
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